Articles: sepsis.
-
Critical care medicine · Mar 2000
Randomized Controlled Trial Multicenter Study Clinical TrialPhase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis.
To evaluate the safety and efficacy of the platelet-activating factor receptor antagonist BB-882 in the treatment of patients with sepsis. ⋯ Treatment of sepsis with the platelet-activating factor antagonist BB-882 offers no advantage over placebo on survival, hemodynamic status, respiratory function, or organ failure scores.
-
Randomized Controlled Trial Clinical Trial
[Early jejunal feeding in acute pancreatitis: prevention of septic complications and multiorgan failure].
Authors evaluate the effect of early jejunal feeding on septic complications and mortality in acute pancreatitis, based on the results of a two-phase, prospective, randomized study. In the first part of the study they compared the conventional parenteral nutrition with early (started within 24 hours) enteral nutrition in a prospective, randomized trial on 89 patients. Forty-eight patients were randomized into the parenteral group "A" (Rindex 10, Infusamin S, Intralipid 10%: 30 kcal/kg) and 41 patients into the enteral group "B" (fed by nasogastric jejunal tube Survimed OPD, 30 kcal/kg). ⋯ In the second phase of the study early jejunal feeding was combined with imipenem prophylaxis (Tienam, 2 x 500 mg i.v.) in the necrotizing cases detected by CT scan. According to the results of 92 patients the rate of septic complications (p = 0.03), multiple organ failure (p = 0.14), and mortality (p = 0.13) were further reduced in this group. Authors believe that combination of early enteral nutrition and a selective, adequate antibiotic therapy may give a chance for prevention of multiple organ failure.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Prospectively validated predictions of shock and organ failure in individual septic surgical patients: the Systemic Mediator Associated Response Test.
Clinically useful predictions of end-organ function and failure in severe sepsis may be possible through analyzing the interactions among demographics, physiologic parameters, standard laboratory tests, and circulating markers of inflammation. The present study evaluated the ability of such a methodology, the Systemic Mediator Associated Response Test (SMART), to predict the clinical course of septic surgery patients from a database of medical and surgical patients with severe sepsis and/or septic shock. ⋯ SMART multivariate models accurately predict pathophysiology, shock, and organ failure in individual septic surgical patients. These prognostications may facilitate early treatment of end-organ dysfunction in surgical sepsis.
-
Critical care medicine · Jan 2000
Randomized Controlled Trial Clinical TrialPrevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins.
To investigate the activity of intravenous immunoglobulin (IVIG) as a prophylactic agent against infection in trauma victims. ⋯ Trauma patients receiving high doses of IVIG exhibit a reduction of septic complications and an improvement of SBA. Early SBA measurement may represent an index of susceptibility to infection.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis.
To determine whether therapy with intravenous immunoglobulin G (IVIG) would decrease mortality in neonatal sepsis. ⋯ In the sample studied therapy with IVIG did not reduce mortality in neonatal sepsis